$3.20
-0.01 (-0.31%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AVXL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional
Held by 10 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +5 more) · FINRA short interest 14.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of ANAVEX3-71 in Adults With SchizophreniaNCT06245213Single Dose Maximum Observed Plasma Concentration (Cmax)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: ANAVEX3-71 oral capsules, Placebo oral capsules | Schizophrenia | 71 | 2025-06-30 | 2025-05-04 |
| OLE of Phase 2b/3 Study ANAVEX2-73-AD-004NCT04314934Number of participants with treatment-related adverse events as assessed by CTCAE v4.03Open-label · Treatment | Phase 2/3 | Completed | Drug: ANAVEX2-73 | Alzheimer Disease | 300 | 2024-06-14actual | 2024-08-12 |
| ANAVEX2-73 Study in Pediatric Patients With Rett SyndromeNCT04304482RSBQRandomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: ANAVEX2-73 oral liquid, Placebo oral liquid | Rett Syndrome | 92 | 2023-06-01actual | 2023-08-21 |
| ANAVEX2-73 for Treatment of Early Alzheimer's DiseaseNCT03790709ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Completed | Drug: High dose ANAVEX2-73, Mid dose ANAVEX2-73, Placebo oral capsule | Alzheimer Disease | 509 | 2022-06-30actual | 2022-07-14 |
| OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001NCT04575259Number of participants with treatment-related adverse events as assessed by CTCAE v4.03Open-label · Treatment | Phase 2 | Completed | Drug: ANAVEX2-73 | Parkinson Disease Dementia | 132 | 2022-05-31actual | 2022-08-01 |
| ANAVEX2-73 Study in Patients With Rett SyndromeNCT03941444RSBQRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: ANAVEX2-73, Placebo | Rett Syndrome | 33 | 2021-09-30actual | 2022-01-27 |
| Phase 1 Study of ANAVEX3-71NCT04442945Evaluation of safety and tolerability of ANAVEX3-71 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs) Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ANAVEX3-71, Placebo | Healthy | 36 | 2021-09-30actual | 2022-01-19 |
| An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's DiseaseNCT02756858Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Open-label · Treatment | Phase 2 | Completed | Drug: ANAVEX2-73 | Alzheimer's Disease | 21 | Nov 2020actual | 2021-01-12 |
| Study of ANAVEX2-73 in Patients With Rett SyndromeNCT03758924Incidence of Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ANAVEX2-73, Placebo | Rett Syndrome | 31 | 2020-10-30actual | 2021-01-12 |
| ANAVEX2-73 Study in Parkinson's Disease DementiaNCT03774459Cognitive Drug Research (CDR) Computerized Assessment System Continuity of AttentionRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: High dose ANAVEX2-73, Mid dose ANAVEX2-73, Placebo oral capsule | Parkinsons Disease With Dementia | 132 | 2020-09-30actual | 2020-10-22 |
| Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's DiseaseNCT02244541To determine maximum tolerated dose of Anavex2-73.Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: ANAVEX2-73 Oral, ANAVEX2-73 Intravenous, ANAVEX2-73 Oral, ANAVEX2-73 Oral | Alzheimer's Disease | 32 | Nov 2015actual | 2018-11-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19